GSK and AN2 Therapeutics Collaborate to Advance Boron-Based LeuRS-Inhibitors for TB Treatment

AN2 Therapeutics has announced a collaboration with GSK to develop new treatments for tuberculosis (TB) using its boron chemistry platform. The collaboration aims to address the urgent global health challenge of TB, which affects over a quarter of the world's population and causes over 1.25 million deaths annually. AN2's boron chemistry platform has already led to the development of epetraborole, ganfeborole, and tavaborole, and the company is hopeful that this approach may contribute to addressing TB patients' significant unmet needs in the future.